2. Academic Validation
  3. Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study

Substituted pteridinones as p90 ribosomal S6 protein kinase (RSK) inhibitors: A structure-activity study

  • Bioorg Med Chem. 2020 Mar 1;28(5):115303. doi: 10.1016/j.bmc.2019.115303.
Kimberly A Casalvieri 1,  Christopher J Matheson 1,  Donald S Backos 1,  Philip Reigan 2
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 East Montview Boulevard, Aurora, CO 80045, USA.
  • 2 Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 East Montview Boulevard, Aurora, CO 80045, USA. Electronic address: philip.reigan@cuanschutz.edu.
PMID: 31982240 DOI: 10.1016/j.bmc.2019.115303
Abstract

The activity of p90 ribosomal S6 kinase 2 (RSK2) has emerged as an attractive target for Cancer therapy due to its role in the regulation of diverse cellular processes, such as cell transformation and proliferation. Several pan-RSK inhibitors have been identified with BI-D1870 and the pseudo-analogs LJH685 and LJI308 being the most selective, potent, and frequently used small molecule inhibitors. We designed and synthesized a series of pteridinones and pyrimidines to evaluate the structural features of BI-D1870 that are required for RSK2 inhibition. We have identified inhibitors of RSK2 activity, evaluated their target engagement in cells, and measured their effect on cell viability and cytotoxicity in the MOLM-13 acute myeloid leukemia (AML) cell line. The results of our studies support that RSK2 inhibition can be achieved in MOLM-13 cells without potent cytotoxicity. The structure-activity data from this study will be used as a platform to develop novel RSK2 inhibitors.

Keywords

Cancer; Inhibitor; Kinase; Pteridinones; RSK2.

Figures